🔥Telegram İfşa

We recently spoke with Adam Kittai, of Icahn School of Medicine at Mount Sinai/The Tisch Cancer Institute, on practice-changing studies in #CLL! From AMPLIFY to TRANSCEND 004, these trials are paving the way for more treatment options. 📚 Read here: buff.ly/ze6U8XN

Preview our systematic review and meta-analysis in Blood Advances out now... should assessment of clonal relatedness of CLL and RT-DLBCL be the sole factor for Richter transformation prognostication? TLDR: no! Toby Eyre ashpublications.org/bloodadvances/…

🚨 Transforming Lymphoma & CLL Treatment! 🚨 📣 Join us as we spotlight 🌟 Dr. Adam Kittai 🌟 of Icahn School of Medicine at Mount Sinai, a leading expert CLL research, as he breaks down the latest advances in Richter Transformation at MedNews Week’s Medical Spotlight, in

Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia. ashpublications.org/blood/article-…

When CLL Shape-Shifts, Lymphoma Is the Dreaded Result medscape.com/viewarticle/wh… Adam Kittai highlights two recent studies combining immunotherapy with targeted agents. Icahn School of Medicine at Mount Sinai #CLL #lymphoma

#Hematology Acquired mutations in patients with relapsed/refractory #CLL who progressed in the ALPINE study | ⁦@BloodJournal⁩ | American Society of Hematology ⁦ASH⁩ #lymsm ashpublications.org/bloodadvances/…

.Adam Kittai reports on Richter transformation and is leading a new clinical trial of CAR-T cell therapy along the BTK inhibitor zanubrutinib. mountsinai.org/about/newsroom… Icahn School of Medicine at Mount Sinai

.Adam Kittai publishes three studies advancing treatment for rare and aggressive lymphoma medicalxpress.com/news/2025-06-p… via Medical Xpress Icahn School of Medicine at Mount Sinai #CLL

#Hematology International consensus statement on diagnosis, evaluation, and research of #Richter transformation: the ERIC recommendations | ⁦Blood Journals Portfolio⁩ | American Society of Hematology #lymsm ashpublications.org/blood/article/…

Long overdue publication of our IST of copanlisib-nivo in transformed FL and Richter serving as proof that immunotherapy may make a difference; sustained T cell IFN signaling is predictive of response in RT. Our next Richter project deploys bi-specifics. haematologica.org/article/view/1…

ERIC recently published recommendations for the diagnosis, management, and research of Richter's transformation. Read our feature article covering the recommendations and emerging therapies in clinical trial for RT👇 🌟 ow.ly/hF6F50WFVcx.🌟 Featuring expert insights from

Congratulations to @joshuabrodyMD and Team for winning the Blood Cancer United $1.75M RAFL Award to further the Mount Sinai Health System The Tisch Cancer Institute Lipschultz Precision Immunology Institute mission to eradicate lymphomas and other blood cancers! bit.ly/45VUDca bloodcancerunited.org/research/grants

The deadline for the #NashvilleHeme26 poster competition is just a few weeks away! 👩‍💼 Medical residents, hematology or oncology fellows, and junior faculty within 2 years of initial appointment, submit your abstract relevant to hematologic malignancies for the chance to be